**In vivo Mouse Models of Bacterial Infection**

**Neutropenic Thigh Model**

**Introduction**

Complicated skin and soft tissue infections are frequently encountered in clinical practice and are a significant cause of morbidity and mortality in hospitalized patients. The neutropenic mouse thigh model of infection has been used extensively to test and benchmark antimicrobial drugs leading to a significant impact on our current knowledge of antimicrobial pharmacology. This model allows the quantitative comparison of different agents and different dosing regimens and the determination of the time-course of antimicrobial activity under conditions optimal for efficacy, i.e., neutropenia. Because the pharmacology of antimicrobial agents is affected by the presence of neutrophils, animals are commonly rendered neutropenic with cytotoxic agents like cyclophosphamide, the most frequently used immunosuppressive agent in animal infection models.

ImQuest BioSciences, in collaboration with Noble Life Sciences, has successfully developed a neutropenic mouse thigh model and demonstrated its use in a study to evaluate vancomycin for the treatment of a *Staphylococcus aureus* infection. The model will serve as a platform for the evaluation of the efficacy of novel antimicrobial compounds in the treatment of microbial infections.

**Methodology**

Twenty-one 5 to 6 week old female ICR (CD1) mice were made neutropenic by administration of two doses of cyclophosphamide (150 mg/kg and 100 mg/kg per mouse on days 1 and 4, respectively).

On Day 5, 18 mice were challenged with 0.1 mL of a 10^7 colony forming units (CFU) per mL of *Staphylococcus aureus* 29213 by intramuscular injection in the right thigh. One group of 3 mice (Group 2) was sacrificed 2 hours post inoculation and the other mice in groups of 3 mice each were treated with vancomycin (Groups 4-7) or vehicle control (Groups 1 and 3) at 2, 8, and 14 hours post-inoculation.

At 24-hours post inoculation (Groups 1, 2-7) or 2-hours post inoculation (Group 2), mice were sacrificed and the right thigh aseptically removed, weighed, and placed in a tube on ice. Thighs were transferred to 15 mL polypropylene tubes and homogenized in 3 mL of...
sterile PBS with a hand held IKA works T25 generator with sterile 7 mm x 110 mm disposable rotor stator probe.

Serial ten-fold dilutions of the thigh homogenates were prepared in sterile PBS and 0.1 mL of four dilutions for each thigh was plated onto trypticase soy agar plates containing 5% sheep’s blood, in duplicate. Bacterial colonies were enumerated for each plate following about 20 hours of incubation at 37°C.

Results

Results of colony counts are presented in Fig 1. Vancomycin effectively inhibited the replication of *Staphylococcus aureus* resulting in a 4.4 (100 mg/kg) to 5.2 (800 mg/kg) log<sub>10</sub> reduction in CFU/gram in the treated animals compared to the untreated (Group 3) animals. No colonies were observed on plates for undiluted thigh homogenates from Group 1 animals. Back calculation of colonies from the Group 2 animals indicated that the starting inoculum was 1.3 x 10<sup>6</sup> CFU/mL.

The results reported herein were derived from a collaborative effort combining the microbiology expertise of ImQuest BioSciences (Frederick, MD) with the animal model and drug development expertise of Noble Life Sciences (Gaithersburg, MD).

The demonstrated success of this collaborative effort will allow for routine performance of animal models of infection, including the neutropenic thigh model, for the evaluation of new anti-microbial agents.

ImQuestSUCCESS

*Select drug candidates with the highest probability of clinical success*

The ImQuestSUCCESS preclinical services platform is used to critically evaluate the potential of a test compound and to assure that its efficacy, toxicity, and pharmaceutical properties are evaluated in a comprehensive and interactive way. Successful completion of platform objectives provides significant confidence in the potential of a test compound to transition to human clinical trials, enhances the robustness of drug development efforts and reduces the risk of expensive clinical development failures by the exclusion of candidates which are likely to fail during advanced preclinical and clinical development at early (and less expensive) time points.